Protection from bb rat diabetes by the platelet-activating factor inhibitor BN50730
(1993) In Autoimmunity 16(4). p.259-266- Abstract
The platelet-activating factor inhibitor BN50730, a hetrazepine, was injected intraperitoneally daily from 30 days of age into diabetes-prone BB rats. While 96% (22123) Tween 80 injected control rats developed diabetes, 0.05 mg/kg BN50730 decreased the frequency to 72% (17/24;n.s.) and 0.5 mg/kg to 56% (14125;p <0.01). Mean onset age in controls was 81 ± 9 days (mean ± SD), but BN50730 delayed onset to 87 ± 15 days in the low and 93 ± 12.days (p <0.01) in high dose rats. The relative degree of insulitis was reduced in both low (p <0.01) and high (p <0.05) dose treated groups. Serum insulin in young prediabetic controls decreased from 84±34 μU/ml to 38 ± 20 in the 22 rats developing diabetes (p <0.001). Serum insulin in... (More)
The platelet-activating factor inhibitor BN50730, a hetrazepine, was injected intraperitoneally daily from 30 days of age into diabetes-prone BB rats. While 96% (22123) Tween 80 injected control rats developed diabetes, 0.05 mg/kg BN50730 decreased the frequency to 72% (17/24;n.s.) and 0.5 mg/kg to 56% (14125;p <0.01). Mean onset age in controls was 81 ± 9 days (mean ± SD), but BN50730 delayed onset to 87 ± 15 days in the low and 93 ± 12.days (p <0.01) in high dose rats. The relative degree of insulitis was reduced in both low (p <0.01) and high (p <0.05) dose treated groups. Serum insulin in young prediabetic controls decreased from 84±34 μU/ml to 38 ± 20 in the 22 rats developing diabetes (p <0.001). Serum insulin in BN50730-protected compared to unprotected rats was 114±49 and 32±22 (p <0.001) in the low, and 91 ± 4 6 and 21 ± 15 (p <0.001) μU/ml in the high dose group, respectively. Increased serum insulin correlated with preserved islet β cells and decreased insulitis. Treatment did not affect thyroiditis. Thus, platelet-activating factor may be involved in insulitis pathogenesis and platelet-activating factor inhibitors may decrease autoimmune β cell destruction.
(Less)
- author
- Jobe, Lance W. ; Ubungen, Roel ; Goodner, Charles J. ; Baskin, Denis G. ; Braquet, Pierre and Lernmark, Åke LU
- publishing date
- 1993-01-01
- type
- Contribution to journal
- publication status
- published
- keywords
- Biobreeding (BB) rats, IDDM (insulin-dependent diabetes mellitus), Insulitis, PAF
- in
- Autoimmunity
- volume
- 16
- issue
- 4
- pages
- 259 - 266
- publisher
- Taylor & Francis
- external identifiers
-
- scopus:0027889129
- pmid:8025205
- ISSN
- 0891-6934
- DOI
- 10.3109/08916939309014644
- language
- English
- LU publication?
- no
- id
- c2ad08a7-e818-4ee6-b386-3baf70ec5704
- date added to LUP
- 2019-09-11 09:24:16
- date last changed
- 2024-03-13 08:17:11
@article{c2ad08a7-e818-4ee6-b386-3baf70ec5704, abstract = {{<p>The platelet-activating factor inhibitor BN50730, a hetrazepine, was injected intraperitoneally daily from 30 days of age into diabetes-prone BB rats. While 96% (22123) Tween 80 injected control rats developed diabetes, 0.05 mg/kg BN50730 decreased the frequency to 72% (17/24;n.s.) and 0.5 mg/kg to 56% (14125;p <0.01). Mean onset age in controls was 81 ± 9 days (mean ± SD), but BN50730 delayed onset to 87 ± 15 days in the low and 93 ± 12.days (p <0.01) in high dose rats. The relative degree of insulitis was reduced in both low (p <0.01) and high (p <0.05) dose treated groups. Serum insulin in young prediabetic controls decreased from 84±34 μU/ml to 38 ± 20 in the 22 rats developing diabetes (p <0.001). Serum insulin in BN50730-protected compared to unprotected rats was 114±49 and 32±22 (p <0.001) in the low, and 91 ± 4 6 and 21 ± 15 (p <0.001) μU/ml in the high dose group, respectively. Increased serum insulin correlated with preserved islet β cells and decreased insulitis. Treatment did not affect thyroiditis. Thus, platelet-activating factor may be involved in insulitis pathogenesis and platelet-activating factor inhibitors may decrease autoimmune β cell destruction.</p>}}, author = {{Jobe, Lance W. and Ubungen, Roel and Goodner, Charles J. and Baskin, Denis G. and Braquet, Pierre and Lernmark, Åke}}, issn = {{0891-6934}}, keywords = {{Biobreeding (BB) rats; IDDM (insulin-dependent diabetes mellitus); Insulitis; PAF}}, language = {{eng}}, month = {{01}}, number = {{4}}, pages = {{259--266}}, publisher = {{Taylor & Francis}}, series = {{Autoimmunity}}, title = {{Protection from bb rat diabetes by the platelet-activating factor inhibitor BN50730}}, url = {{http://dx.doi.org/10.3109/08916939309014644}}, doi = {{10.3109/08916939309014644}}, volume = {{16}}, year = {{1993}}, }